Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1 Department of Psychiatry, University of Texas Health Science Center, San Antonio, TX (США); 2 Neurological Outcomes Center, University Hospitals Case Medical Center, Cleveland, OH, USA (США)
Список исп. литературыСкрыть список 1. Lacro JP, Dunn LB, Dolder CR et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002;63:892-909. 2. Velligan D, Mintz J, Maples N et al. A randomized trial comparing in-person and electronic interventions for improving adherence to oral medication in schizophrenia. Schizophr Bull (in press). 3. Weiden PJ, Solari H, Kim S et al. Longacting injectable antipsychotics and the management of non-adherence. Psychiatr Ann 2011;41:271-8. 4. Velligan DI, Medellin E, Draper M et al. Barriers to and solutions for starting a long-acting injection clinic in a community mental health center. Commun Ment Health J 2011;47:654-9. 5. Kishimoto T, Nitta M, Borenstein M et al. Long acting injectable vs. oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. Presented at the 51st Annual Meeting of the American College of Neuropsychopharmacology, Hollywood, December 2012. 6. Weiden P, Velligan DI, Roma RS et al. Getting to “no”: how the perceived threat to the therapeutic alliance posed by longacting injectable antipsychotic therapy negatively influences therapist recommendations. Presented at the 24th Annual US Psychiatric and Mental Health Congress, Las Vegas, November 2011. 7. Roma RS, Velligan DI, Weiden et al.When the patient’s “Yes” is not enough:ethnographic observation of physician resistance when recommending antipsychotic long-acting therapy. Presented at the 24th Annual US Psychiatric and Mental Health Congress, Las Vegas, November 2011. 8. Velligan DI, Diamond PM, Mintz J et al. The use of individually tailored environmental supports to improve medication adherence and outcomes in schizophrenia. Schizophr Bull 2008;34:483-93.